Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mediator complex subunit 1 (MED1) is a central component of the Mediator complex, a multiprotein assembly that serves as a bridge between gene-specific regulatory proteins—especially nuclear hormone receptors—and the general RNA polymerase II transcription machinery[7][6][2]. MED1 directly binds and coactivates a diverse range of transcription factors, including nuclear receptors (such as estrogen receptor, peroxisome proliferator-activated receptor gamma, and thyroid hormone receptor), master developmental regulators (such as GATA-1), and tumor suppressors (such as p53), to modulate gene transcription[7][2][4][5]. MED1 displays critical roles in cell fate determination, proliferation, differentiation, and apoptosis; it is indispensable in mammalian development, as its genetic deficiency leads to embryonic lethality with developmental defects[4]. MED1 also acts as a key regulator of DNA damage response by partnering with BRCA1 and supporting homologous recombination repair[3]. Overexpression or deregulation of MED1 is implicated in cancer, including as a negative prognostic marker in breast tumors, where it enhances proliferation, migration, and endocrine response through interactions with ER-alpha and specific microRNAs[1]. Its broad and essential functions render it a challenging but potentially valuable target in malignancies driven by dysregulated nuclear receptor signaling or transcriptional control.
Modulation of gene expression via coactivation of nuclear receptors (e.g., estrogen receptor, peroxisome proliferator-activated receptor gamma, thyroid hormone receptor) Regulation of transcriptional complexes involving tumor suppressors (e.g., p53), hormone receptors, and DNA repair proteins (e.g., BRCA1)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mediator complex subunit 1 (MED1).